EASI Revenue and Competitors
Estimated Revenue & Valuation
- EASI's estimated annual revenue is currently $176.5M per year.
- EASI's estimated revenue per employee is $240,800
Employee Data
- EASI has 733 Employees.
- EASI grew their employee count by -12% last year.
EASI's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Project Manager | Reveal Email/Phone |
2 | Quality Auditor/Project Manager | Reveal Email/Phone |
3 | Program Manager | Reveal Email/Phone |
4 | Engineering Manager | Reveal Email/Phone |
5 | Project Manager | Reveal Email/Phone |
6 | Practice Manager | Reveal Email/Phone |
7 | Program Manager | Reveal Email/Phone |
8 | Sr. Manager | Reveal Email/Phone |
9 | Program Manager | Reveal Email/Phone |
10 | Project Manager Field Svc | Reveal Email/Phone |
EASI Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $176.5M | 733 | -12% | N/A | N/A |
#2 | $65.1M | 303 | 3% | N/A | N/A |
#3 | $8.4M | 54 | 17% | N/A | N/A |
#4 | $4.4M | 32 | 7% | N/A | N/A |
#5 | $271.1M | 1126 | 89% | N/A | N/A |
#6 | $6.6M | 48 | -23% | N/A | N/A |
#7 | $6.2M | 45 | 0% | N/A | N/A |
#8 | $2M | 19 | -10% | N/A | N/A |
#9 | $29.9M | 148 | 169% | N/A | N/A |
What Is EASI?
Business Services
keywords:N/A
N/A
Total Funding
733
Number of Employees
$176.5M
Revenue (est)
-12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
EASI News
2022-04-20 - Global Cardiac Holter Monitor Market Analysis/Forecasts 2022-2027: Industry
Trends, Share, Growth, Insights, Impact of COVID-19, Company Analysis -
ResearchAndMarkets.com
Five EASI electrodes collect three channels of derived 12-Lead ECG, allowing for quick access to high-quality patient data and extending the...
2022-04-19 - Global Virgin Human Hair Market 2022 Major Growth and Top ...
Rebecca; Great Lengths; Hair Dreams; Easi Hair; Balmain; Donna Bella; Cinderella; Socap; Anhui Jinruixiang; Ruimei; Evergreen Products Group; Hairlocs...
2022-04-06 - LEO Pharma Presents New Interim Long-Term Efficacy Data for Adbry
(tralokinumab-ldrm) in Moderate-to-Severe Atopic Dermatitis at the 2022 RAD
Conference
In patients who completed 3 years of treatment with Adbry, the median Eczema Area and Severity Index (EASI) score improved by 93% (2.0 at 3...
Other Companies in Severn
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $552.4M | 1203 | 16% | N/A |
#2 | $75M | 1486 | 10% | N/A |
#3 | $662.3M | 2075 | 17% | N/A |
#4 | $482.2M | 2870 | -5% | N/A |
#5 | $562.5M | 3348 | 7% | N/A |